Cellectar BioSciences CLRBW 深 沪
已收盘 09-25 16:00:00 美东时间
0.13
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.13
- 总市值 2311.00万
- 52周最高 0.26
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.021
- 委 比 0.00%
- 总股本 1.78亿
- 历史最高 0.79
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.021
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cellectar BioSciences FY 2025 net loss USD 21.8 million
Cellectar BioSciences FY 2025 net loss USD 21.8 million Cellectar BioSciences reported a FY 2025 net loss of USD 21.8 million, or USD 8.35 per basic and diluted share. R&D expenses were USD 11.5 million and G&A expenses were USD 11.5 million for FY 2025, with total operating expenses of USD 23.0 mil
03-04 20:15
Cellectar Biosciences Secures New Patents to Strengthen Global Cancer Drug Portfolio
Cellectar Biosciences Secures New Patents to Strengthen Global Cancer Drug Portfolio Cellectar BioSciences Inc. has announced the expansion of its global intellectual property estate, with newly issued patents across Europe, Asia-Pacific, the Middle East, and the Americas. The patents cover the comp
02-17 21:05
Cellectar BioSciences Unveils Pipeline Advancements in Phospholipid Drug Conjugate Oncology Therapies
Cellectar BioSciences Inc. has outlined key developments in its phospholipid drug conjugate (PDC) platform, highlighting progress in multiple oncology therapeutic programs. The company is advancing it...
2025-12-06 06:49
Cellectar BioSciences Inc. to Release Third Quarter Financial Results
Cellectar BioSciences Inc. will report third quarter financial results on November 13, 2025. A conference call and webcast to discuss the results will be held the same day at 8:30 a.m. Eastern Time. T...
2025-11-06 21:06
Cellectar BioSciences raises 58 million from warrant exercises and issues new inducement warrants totaling 1048094 shares
Cellectar BioSciences Inc. entered into inducement offer agreements with certain holders of existing warrants originally issued on October 25, 2022, July 21, 2024, and July 2, 2025. The holders agreed...
2025-10-11 04:31
Cellectar BioSciences COO Jarrod Longcor Reports Acquisition of Common Shares
Jarrod Longcor, the Chief Operating Officer of Cellectar BioSciences Inc., reported an acquisition of common shares of the company. The full filing can be accessed through the link below. Disclaimer: ...
2025-07-03 20:01
Cellectar BioSciences Inc. CFO Chad J. Kolean Acquires Common Shares
Chad J. Kolean, Chief Financial Officer, reported an acquisition of common shares of Cellectar BioSciences Inc. The full filing can be accessed through the link below. Disclaimer: This news brief was ...
2025-07-03 20:00
Cellectar BioSciences Inc. Conducted Annual Stockholders Meeting
Cellectar BioSciences Inc. held its 2025 Annual Meeting of Stockholders on June 13, 2025. During the meeting, James V. Caruso and Frederick W. Driscoll were elected as Class II directors. The appointm...
2025-06-14 04:31
Cellectar BioSciences Inc. Unveils New Presentation on Phospholipid Drug Conjugates and Promising Advances in Oncology Treatments
Cellectar BioSciences Inc. has presented its latest corporate presentation, highlighting the development of Phospholipid Drug Conjugates (PDCs). The company has validated its PDC platform, which shows...
2025-05-07 01:49
快讯 | Cellectar BioSciences将在即将举行的JP摩根健康会议上的生物技术展会上强调2025年战略措施
Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming...
2025-01-13 07:00
